NEW YORK, July 24, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the following equities: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Orexigen Therapeutics Inc. (NASDAQ: OREX), Prana Biotechnology Ltd (NASDAQ: PRAN), and Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP). Free research report on Synergy Pharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=SYGP On Thursday, July 23, 2015, the NASDAQ Composite ended at 5,146.41, down 0.49%, the Dow Jones Industrial Average declined 0.67%, to finish the day at 17,731.92, and the S&P 500 closed at 2,102.15, down 0.57%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
Synergy Pharmaceuticals Inc.'s stock finished Thursday's session 1.64% lower at $8.42. A total of 3.41 million shares were traded, which was below its three months average volume of 5.52 million shares. Over the last one month and the previous three months, Synergy Pharmaceuticals Inc.'s shares have surged 3.69% and 104.87%, respectively. Additionally, the stock has rallied 176.07% since the beginning of 2015. The company's shares are trading above their 50-day and 200-day moving averages by 28.09% and 105.26%, respectively. Synergy Pharmaceuticals Inc.'s stock has a Relative Strength Index (RSI) of 53.19. Sign up and read the free notes on SYGP at:
On Thursday, shares in Teva Pharmaceutical Industries Ltd ended the session flat at $62.51. The stock reported a trading volume of 1.53 million shares, below its three months average volume of 3.87 million shares. Shares of the company traded at a PE ratio of 19.47. Although, Teva Pharmaceutical Industries Ltd's shares have lost 0.62% in the previous three months, it has advanced 4.53% in the last one month and 9.96% on YTD basis. The stock is trading 2.47% above its 50-day moving average and 6.99% above its 200-day moving average. Moreover, shares of Teva Pharmaceutical Industries Ltd have an RSI of 55.18. The complimentary notes on TEVA can be downloaded in PDF format at:
Orexigen Therapeutics Inc.'s stock declined 4.02%, to close the day at $3.82. The stock recorded a trading volume of 4.85 million shares, much above its three months average volume of 2.54 million shares. Over the last one month and over the past three months, Orexigen Therapeutics Inc.'s shares have declined 22.98% and 48.66%, respectively. Furthermore, the stock has plummeted 36.96% since the start of this year. The company's shares are trading 20.28% below their 50-day moving average and 32.58% below their 200-day moving average. Additionally, Orexigen Therapeutics Inc. has an RSI of 25.55. Register for free on Equity Research Institute and access the latest research on OREX at:
On Thursday, shares in Prana Biotechnology Ltd recorded a trading volume of 0.09 million shares, lower than their three months average volume of 0.53 million shares. The stock ended the day 2.56% higher at $1.20. Although, Prana Biotechnology Ltd's stock has advanced 7.14% in the past three months, it has declined 9.09% in the last one month and 26.83% on YTD basis. The company is trading below its 50-day and 200-day moving averages by 6.34% and 16.30%, respectively. Furthermore, shares of Prana Biotechnology Ltd have an RSI of 48.37. The complete research on PRAN is available for free at:
Sucampo Pharmaceuticals Inc.'s stock lost 5.77%, to close Thursday's session at $19.60. The stock recorded a trading volume of 0.78 million shares, above its three months average volume of 0.54 million shares. Over the last one month and since the start of this year, Sucampo Pharmaceuticals Inc.'s shares have surged 14.55% and 37.25%, respectively. However, the stock has lost 8.41% in the previous three months. The company is trading 15.55% and 31.74% above its 50-day and 200-day moving averages, respectively. Furthermore, Sucampo Pharmaceuticals Inc.'s stock traded at a PE ratio of 47.80 and has an RSI of 57.59. Free in-depth research on SCMP is available at:
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
ERI has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.
ERI, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.equityresearchinstitute.com.
ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.